Replacement of Lamivudine by Telbivudine to Improve Renal Function

• Status: Completed
• Trial end date: 2017-01-31
• Target enrollment: 0
• Participant gender: All

Summary

Nephrotoxicity is one of the adverse effects of lamivudine and dosage of lamivudine has to be reduced if patients' renal function is insufficiency. Telbivudine may improve glomerular filtration rate. This study is to see whether renal function is improved when Lamivudine is replaced by telbivudine in liver transplantation patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chang Gung Memorial Hospital
• Treatments: Lamivudine; Telbivudine

Criteria

Inclusion Criteria:

1. Sign inform consent

2. Age is not less than 16 years old.

3. Post liver transplantation patient for HBV-related indication.

4. Chronic hepatitis B transplant patients who are treated by lamivudine for not less than 6 months.

5. eGRF stage 2-4 patients (156. Stable liver function, ALT not more than 2 folds of upper limit.

Exclusion Criteria:

1. Acute rejection with increase CNI dose within a month.

2. Pregnant or nursing.